988O A phase I/II trial (LOKON003) evaluating tumor microenvironment (TME) gene engineering using a viral vector combined with atezolizumab in advanced malignant melanoma von Hamid, O., Rydén, V., Mehmi, I., Wang, D., Patel, M., Krause, J., Sandin, L.C., Grauers Wiktorin, H., Lövgren, T., Eriksson, E., Leja Jarblad, J., Loskog, A., Ullenhag, G.J.

Volltext

P03.27 Role of NOX2 for hypoxia-induced chemoresistance in acute myeloid leukemia von Paul, S, H Grauers Wiktorin, Kiffin, R, Hellstrand, K, Martner, A

Volltext

Reduced immunogenicity of a third COVID-19 vaccination among recipients of allogeneic hematopoietic stem cell transplantation von Einarsdottir, Sigrun, Martner, Anna, Nicklasson, Malin, Wiktorin, Hanna Grauers, Arabpour, Mohammad, Törnell, Andreas, Vaht, Krista, Waldenström, Jesper, Ringlander, Johan, Bergström, Tomas, Brune, Mats, Hellstrand, Kristoffer, Ljungman, Per, Lagging, Martin

Volltext

Impaired SARS-CoV-2-specific T-cell reactivity in patients with cirrhosis following mRNA COVID-19 vaccination von Al-Dury, Samer, Waern, Johan, Waldenström, Jesper, Alavanja, Marko, Saed, Hevar Hamah, Törnell, Andreas, Arabpour, Mohammad, Wiktorin, Hanna Grauers, Einarsdottir, Sigrun, Ringlander, Johan, Ringström, Gisela, Hellstrand, Kristoffer, Martner, Anna, Lagging, Martin

Volltext

Deficiency of SARS-CoV-2 T-cell responses after vaccination in long-term allo-HSCT survivors translates into abated humoral immunity von Einarsdottir, Sigrun, Martner, Anna, Waldenström, Jesper, Nicklasson, Malin, Ringlander, Johan, Arabpour, Mohammad, Törnell, Andreas, Wiktorin, Hanna Grauers, Nilsson, Staffan, Bittar, Rudy, Nilsson, Malin, Lisak, Mikael, Veje, Malin, Friman, Vanda, Al-Dury, Samer, Bergström, Tomas, Ljungman, Per, Brune, Mats, Hellstrand, Kristoffer, Lagging, Martin

Volltext